ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
November 15, 2024InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China -
New compound targets enzyme linked to autoimmune disorders, severe COVID-19
March 12, 2021When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself ...
Pharma Sources Insight January 2025
